| Course | NRNP 6559 Advanced Primary Care of Women and Diverse Populations |
|---|---|
| Week | Week 8 |
| Paper type | Menopause SOAP note |
| Length | About 760 words, 5 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | Master of Science in Nursing (MSN) |
| Updated | October 2026 |
Free sample paper for NRNP 6559 Week 8
Menopause SOAP Note: Hot Flashes, Painful Intercourse, and a Mother's Breast Cancer in a 52-Year-Old With an Intact Uterus
Student Name
College of Nursing, Walden University
NRNP 6559: Advanced Primary Care of Women and Diverse Populations
Instructor Name
Month Day, Year
Menopause SOAP Note: Hot Flashes, Painful Intercourse, and a Mother's Breast Cancer in a 52-Year-Old With an Intact Uterus
Subjective: Vasomotor Symptoms
Composite case. A 52-year-old high school guidance counselor. Hot flashes 8 to 10 times a day, each lasting 2 to 4 minutes, worst in the afternoon; night sweats that wake her 3 times most nights, with a change of nightshirt twice a week. She has stopped wearing wool, keeps a fan at her desk, and has left two student meetings because of flushing. Sleep: about 5 broken hours a night; tired and "short with people" at work. Duration: about 18 months, worsening.
Subjective: Genitourinary Symptoms
Vaginal dryness for about a year; pain with intercourse that has led her and her husband to have sex less than once a month, which she says bothers both of them. Mild burning after intercourse; no urinary frequency, urgency, or infections. She has tried an over-the-counter lubricant with partial relief. These are recorded separately from her hot flashes because they are managed differently and often persist after vasomotor symptoms fade.
Subjective: Mood, Sleep, and Menopause Status
Mood: PHQ-2 score 1; she describes her mood as "fine, just worn out," and still enjoys choir and her garden. Sleep disrupted by sweats, not by worry. Menstrual history: last menstrual period 14 months ago, after a year of irregular cycles. Menopause is established by history, 12 or more months without a period at her age, without hormone testing.
Risk, Gathered in One Place
Her mother was diagnosed with breast cancer at 68, after menopause; no other relatives with breast or ovarian cancer. No personal history of blood clots, stroke, heart attack, or liver disease. Blood pressure 122/78 today; nonsmoker; body mass index 26. Lipids normal last year. Mammogram 7 months ago, normal. Intact uterus; no abnormal bleeding since her last period.
Objective
Vital signs as above. Pelvic exam, chaperone present: vulvar and vaginal tissues pale and thin, with loss of rugae and petechiae after gentle speculum insertion; no lesions or discharge. Uterus small, nontender; no adnexal masses.
Assessment
1. Moderate to severe vasomotor symptoms of menopause, with sleep disruption and effects on work.
2. Genitourinary syndrome of menopause, with dyspareunia and exam findings of vaginal atrophy.
Her individual risk profile for systemic hormone therapy is favorable: she is 52, within 10 years of menopause onset, with no history of clots, stroke, or heart disease, normal blood pressure, and no tobacco use. When therapy starts before age 60 or inside the first decade after the final period, and nothing contraindicates it, the position statement of The Menopause Society, then the North American Menopause Society, judges the benefit-risk ratio favorable for bothersome vasomotor symptoms (North American Menopause Society [NAMS], 2022). Her mother's postmenopausal breast cancer is a factor to discuss openly and weigh, not an automatic reason to refuse therapy. Because her uterus is intact, any systemic estrogen must be paired with a progestogen to protect the endometrium.
Plan: Three Options Compared
Option A, systemic hormone therapy: transdermal estradiol with oral micronized progesterone for endometrial protection. The most effective treatment for vasomotor symptoms (NAMS, 2022), and it also helps genitourinary symptoms and bone. Risks discussed: breast cancer risk with combined therapy over longer durations, and clot and stroke risk, which is lower in her age group and may be lower with the transdermal route. Reassess yearly.
Option B, nonhormonal therapy by class: the 2023 nonhormone position statement recommends cognitive behavioral therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin, fezolinetant, and oxybutynin, and does not recommend supplements or herbal remedies (NAMS, 2023). Less effective than hormone therapy for most women, with no endometrial or breast concern.
Option C, local vaginal therapy for genitourinary symptoms: low-dose vaginal estrogen, with regular moisturizers and lubricants; low-dose vaginal estrogen is effective for these symptoms (NAMS, 2020). It can be used alone or with either option above, and at low vaginal doses a progestogen is generally not needed for endometrial protection, so a woman who chooses Option B for her hot flashes can still treat her genitourinary symptoms with estrogen applied locally.
Her decision, in her words: "I want to sleep again, and I'm willing to try the patch as long as we look at it every year. And yes to the vaginal cream, I want that fixed too." Started: transdermal estradiol patch at a low dose twice weekly, oral micronized progesterone nightly, and low-dose vaginal estradiol cream. Follow-up in 3 months for symptoms, bleeding pattern, and blood pressure; she was told to report any bleeding after the first 6 months, and to continue yearly mammograms.
References
North American Menopause Society. (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 27(9), 976-992. https://doi.org/10.1097/GME.0000000000001609
North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028
North American Menopause Society. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590. https://doi.org/10.1097/GME.0000000000002200
The Walden NRNP 6559 Week 8 instructions
The eighth week of NRNP 6559 typically asks for a SOAP note on menopause management. You quantify vasomotor symptoms, assess genitourinary symptoms, mood and sleep, confirm menopausal status, gather risk factors, and compare treatment options with the patient. Faculty reward individualization over a default answer in either direction. Cite The Menopause Society statements and relevant trials in APA 7. A uterus in place means a progestogen is needed with systemic estrogen. Local vaginal therapy should be considered separately for genitourinary symptoms. Her preferences should visibly steer the choice. Follow-up to judge response is expected, usually within a few months. Quantify the hot flashes and night wakings so the next visit can show whether treatment worked. Record the date of her last period.
Inside the NRNP 6559 Week 8 example
Subjective findings are organized by symptom cluster. Vasomotor symptoms are described by frequency, timing, and effect on sleep and work; genitourinary symptoms, dryness and pain with intercourse, get their own paragraph because they are managed differently; mood and sleep are screened. The menstrual history establishes menopause by the time since her last period. Risk factors are listed where the decision needs them: her mother's breast cancer after menopause, no personal history of clots or stroke, normal blood pressure, and a nonsmoker. The assessment separates the two symptom clusters and states her individual risk profile for systemic hormone therapy, citing The Menopause Society position statement. The plan lays out three options in parallel columns, systemic therapy with a progestogen for her intact uterus, nonhormonal agents by class, and local vaginal therapy, then records her choice.
NRNP 6559 Week 8 rubric: what earns full marks
Individualization is the core of the grade, and a note that either prescribes hormone therapy by default or refuses it because of a family history, without weighing the specifics, has skipped the reasoning The Menopause Society position statement asks for. Here each option is weighed against a stated risk profile. Accuracy about the intact uterus is checked: systemic estrogen without a progestogen in a woman with a uterus is an error graders treat as serious. Separating genitourinary symptoms earns credit, since local therapy carries different risks and many notes miss it. Counseling is graded through the decision record, and a plan that states what she will take without showing what she was offered reads as directive. Sources that describe hormone therapy only through the early Women's Health Initiative reports, without later analyses, tend to lose currency points.
NRNP 6559 Week 8 help: mistakes that cost marks
Menopause notes lose most when hormone therapy is either prescribed by default or refused outright because of a family history, without weighing the details. Explain how her mother's diagnosis affects her own risk. Another common gap is forgetting progestogen protection with an intact uterus. Name it. Writers also treat genitourinary symptoms as part of hot flashes, though local therapy can help them alone. Separate them. Avoid citing old WHI headlines without the later age and timing analyses. Count hot flashes and night wakings so response can be measured. Include nonhormonal options with their evidence. Keep risk factors in one section for clarity. Close with the follow-up interval and what will be reassessed.
Get a NRNP 6559 Week 8 example written to your instructions
Supply the Week 8 case and rubric, noting whether your section asks for specific agents or classes only. The finished note separates the symptom clusters, states a risk profile, compares the options against it with The Menopause Society cited, and records the patient's decision. First custom sample at no cost, delivered within 24-48 hours.
More NRNP 6559 papers and MSN samples
- NRNP 6559 Week 1: Well-Woman Lifespan Post
- NRNP 6559 Week 2: Gynecologic Exam Note
- NRNP 6559 Week 3: Contraception Selection Note
- NRNP 6559 Week 4: Uterine Bleeding Workup
- NRNP 6559 Week 5: STI and Partner Care Note
- NRNP 6559 Week 6: Screening Discussion Post
- NRNP 6559 Week 7: Preconception Note
- NRNP 6559 Week 9: Language Access Case Analysis
- NRNP 6559 Week 10: Gender-Affirming Care Case
- NRNP 6559 Week 11: IPV Advocacy Post
- NRNP 6566 Week 8: Hyponatremia Thread
- NRNP 6557 Week 8: Discussion Post
- NRNP 6567 Week 8: Discussion Post
- NRNP 6549 Week 8: School Performance Case
NRNP 6559 Week 8 questions, answered
What does The Menopause Society position statement say?
Its central position is that hormone therapy decisions should be individualized, weighing the woman's symptoms, her age and time since menopause, and her personal risks, rather than following a blanket rule for or against treatment. The society was formerly known as the North American Menopause Society. The example cites the statement for that principle and applies it to her specific risk profile.
Does her mother's breast cancer rule out hormone therapy?
Not automatically, which is the point the example exists to make. A family history of breast cancer is a factor to weigh, not an absolute bar, and its weight depends on details such as the relative's age at diagnosis and other risks. The note records those details, discusses them with her, and documents how they entered her decision, which is the reasoning graders look for.
Why include nonhormonal options if she might choose hormones?
Because a decision is only informed if the alternatives were on the table. Nonhormonal agents for vasomotor symptoms exist in several classes, and some women prefer them or cannot use estrogen. The example lists them by class with their trade-offs so that her choice, whichever it is, can be shown to follow a real comparison instead of a single recommendation.
Where can I find a free NRNP 6559 Week 8 sample paper?
The 52-year-old's menopause note is printed here with the separate symptom sections, the gathered risk factors and the three options compared.
How are symptoms recorded in NRNP 6559 Week 8?
Vasomotor, genitourinary, mood and sleep symptoms are recorded separately, with risk factors gathered in one place.